LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
| Autor: | Vergote, I.B., Gonzalez Martin, A., Fujiwara, K., Kalbacher, E., Bagameri, A., Ghamande, S., Lee, J-Y., Banerjee, S., Maluf, F.C., Lorusso, D., Yonemori, K., Van Nieuwenhuysen, E., Manso Sanchez, L.M., Woelber, L., Westermann, A.M., Covens, A., Whalley, E., Teng, M.S.L., Soumaoro, I., Slomovitz, B.M. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S1276-S1277 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|